Granulocyte colony-stimulating factors: finding the right indication

Lyman, Gary H.; Shayne, Michelle

doi:10.1097/cco.0b013e3281a3c0ba

Cited by 24 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 This finding has potential therapeutic implications, as it might be possible to reduce doses of growth factors and, consequently, the risk of adverse effects such as cancer. 33,34 However, further specific studies on the vascular niche are needed to investigate in depth its structure and mechanisms linked to PTH activity.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia

et al. 2008

View full text Add to dashboard Cite

show abstract

“…& CMF, with oral cyclophosphamide, was shown equally effective to AC and is an acceptable non-anthracycline containing chemotherapeutic option [72], but it is not less toxic in older breast cancer patients [13,21,73]. Doses should not be reduced, however, because reduction in relative dose intensity of adjuvant chemotherapy regimens results in worse outcomes [74]. & CALGB trial of monotherapy, with capecitabine 2,000 mg/m 2 are less strongly hormone receptor positive and higher grade so are less sensitive to endocrine therapies and more sensitive to chemotherapy [77,78].…”

Section: Hormone Receptor Negative Breast Cancermentioning

confidence: 97%

Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making

Kimmick

2011

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

To prevent breast cancer-related recurrence and death, adjuvant therapy, including chemotherapy, is given. The decision to deliver chemotherapy requires careful weighing of the risk of toxicity versus the estimated benefit. The risk and benefit are based on information from clinical trials, statistical models, and past clinical experience . Compared to younger patients, it is perceived that older patients have cancers that are lower risk, gain less benefit from chemotherapy, and are at higher risk of toxicity. There is now strong evidence that healthy older women tolerate treatment and stand to gain the same benefits from treatment as do younger women. Numeric age alone, therefore, does not justify withholding adjuvant chemotherapy. New tools to aid in the decision are needed. Fortunately, the expected great increase in the size of the geriatric population spawned the field of geriatric oncology and the development of brief, practical versions of the Comprehensive Geriatric Assessment (CGA) for use in busy oncology clinics are in sight. It is time for us to incorporate elements of the CGA into practice, to systematically identify older patients at substantial risk of toxicity. For frail older women with breast cancer, no therapy or less toxic therapies can be considered, some of which are suggested herein. In addition, as always in oncology, physicians and patients should look for and participate in clinical trials that will define how to treat cancer, especially in older patients, in the future.

show abstract

“…Granulocyte-colony stimulating factor (G-CSF) is a member of the hematopoietic growth factor family, which orchestrates the proliferation, differentiation, and survival of hematopoietic progenitor cells [8]. However, growing evidence has suggested that G-CSF also has important nonhematopoietic functions in other tissues including nervous tissues.…”

Section: Introductionmentioning

confidence: 99%

Combination of G-CSF Administration and Human Amniotic Fluid Mesenchymal Stem Cell Transplantation Promotes Peripheral Nerve Regeneration

et al. 2008

View full text Add to dashboard Cite

Amniotic fluid mesenchymal stem cells (AFS) harbor the potential to improve peripheral nerve injury by inherited neurotrophic factor secretion, but present the drawback of the short-term survival after transplantation. Granulocyte-colony stimulating factor (G-CSF) has a diversity of functions, including anti-inflammatory and anti-apoptotic effects. This study was conducted to evaluate whether G-CSF could augment the neuroprotective effect of transplanted AFS against peripheral nerve injury. The potential involvement of anti-inflammation/anti-apoptosis effect was also investigated. Peripheral nerve injury was produced in Sprauge-Dawley rats by crushing left sciatic nerve using a vessel clamp. The AFS were embedded in fibrin glue and delivered to the injured site. G-CSF (50 microg/kg) was administrated by intra-peritoneal injection for 7 consecutive days. Cell apoptosis, inflammatory cytokines, motor function, and nerve regeneration were evaluated 7 or 28 days after injury. Crush injury induced inflammatory response, disrupted nerve integrity, and impaired nerve function in sciatic nerve. Crush injury-provoked inflammation was attenuated in groups receiving G-CSF but not in AFS only group. In transplanted AFS, marked apoptosis was detected and this event was reduced by G-CSF treatment. Increased nerve myelination and improved motor function were observed in AFS transplanted, G-CSF administrated, and AFS/G-CSF combined treatment groups. Significantly, the combined treatment showed the most beneficial effect. In conclusion, the concomitant treatment of AFS with G-CSF augments peripheral nerve regeneration which may involve the suppression of apoptotic death in implanted AFS and the attenuation of inflammatory response.

show abstract

Granulocyte colony-stimulating factors: finding the right indication

Abstract: Consistent clinical practice guidelines based on multiple randomized control trials and meta-analyses should further guide the appropriate and cost-effective use of these agents.

Cited by 24 publications

References 51 publications

Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia

Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia

Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making

Combination of G-CSF Administration and Human Amniotic Fluid Mesenchymal Stem Cell Transplantation Promotes Peripheral Nerve Regeneration

Contact Info

Product

Resources

About